{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:27:55Z","timestamp":1754144875910,"version":"3.41.2"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Cancer-associated thromboembolism (CAT) is a major complication in gastric cancer, impacting patient outcomes. This study aimed to evaluate preoperative thrombocytopenia as a risk factor for CAT in gastric cancer patients undergoing gastrectomy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A retrospective analysis was conducted on 610 gastric cancer patients who underwent D2 gastrectomy between 2005 and 2017. The incidence of CAT and its association with preoperative thrombocytopenia, cancer stage, and recurrence were analyzed. Prognostic factors for CAT and survival were assessed using Kaplan-Meier analysis and Cox regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median follow-up was 67.0 months. Among the study participants, 5.7% (n=35) developed CAT. Preoperative thrombocytopenia was present in 71 patients (11.6%) and older age (\u226565 years) was noted in 308 patients (50.1%). The 5-year incidence rate of CAT was 16.3% in patients with preoperative thrombocytopenia, compared to 4.8% in those with normal platelet counts. Patients with preoperative thrombocytopenia had a higher incidence of CAT compared to those with normal platelet counts (HR = 3.180, 95% CI 1.527-6.623, p = 0.002). Multivariate analysis revealed that thrombocytopenia (HR = 2.202, 95% CI 1.029-4.711, p = 0.042), older age (HR 2.484, 95% CI 1.166-5.290, p = 0.018), stage IV (HR = 2.966, 95% CI 1.106-8.466, p = 0.038) were independent poor prognostic factors for preoperative CAT in gastric cancer patients. Additionally, 29.7% of patients experienced cancer relapse, and 26.1% died during post-treatment follow-up. the patients who developed thromboembolisms had a significantly shorter 5-year OS rate compared with those who did not (56.6% vs. 76.1%, HR = 2.277, 95% CI = 1.376\u20133.767, p = 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Preoperative thrombocytopenia is a significant predictor of CAT in gastric cancer patients. Along with advanced stage and older age, it increases thromboembolic risk and worsens survival. Further studies are needed to refine predictive models and optimize management strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1585201","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T04:13:37Z","timestamp":1752639217000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative thrombocytopenia as a predictor of cancer-associated thromboembolism in gastric cancer patients undergoing gastrectomy"],"prefix":"10.3389","volume":"15","author":[{"given":"Moonki","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song Ee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Hwa","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Gyu","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.551572","article-title":"Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans","volume":"52","author":"Anderson","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199909000-00001","article-title":"Rates of initial and recurrent thromboembolic disease among patients with Malignancy versus those without Malignancy. Risk analysis using Medicare claims data","volume":"78","author":"Levitan","year":"1999","journal-title":"Med (Baltimore)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-017-9981-2","article-title":"Venous thromboembolism is an independent predictor of mortality among patients with gastric cancer","volume":"49","author":"Fuentes","year":"2018","journal-title":"J Gastrointest Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejca.2008.09.005","article-title":"Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the \u2018GISCAD-alternating schedule\u2019 study findings","volume":"45","author":"Mandala","year":"2009","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.2150","article-title":"Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival","volume":"24","author":"Alcalay","year":"2006","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm284","article-title":"Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients","volume":"18","author":"Mandala","year":"2007","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13378","article-title":"Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer","volume":"14","author":"Mansfield","year":"2016","journal-title":"J Thromb Haemost"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005966","article-title":"Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study","volume":"5","author":"Carney","year":"2021","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25537","article-title":"TNM seventh edition: what\u2019s new, what\u2019s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer","volume":"116","author":"Sobin","year":"2010","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(14)50011-4","article-title":"Thrombocytopenia in cancer patients","author":"Liebman","year":"2014","journal-title":"Thromb Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008644","article-title":"The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis","volume":"7","author":"Hsu","year":"2023","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.01.036","article-title":"Formation of procoagulant microparticles and properties","author":"Freyssinet","year":"2010","journal-title":"Thromb Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24539","article-title":"Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer","volume":"229","author":"Sharma","year":"2014","journal-title":"J Cell Physiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06598-8","article-title":"Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis","volume":"30","author":"Frere","year":"2022","journal-title":"Support Care Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"102684","DOI":"10.1016\/j.rpth.2025.102684","article-title":"Anticoagulant management of cancer-associated thrombosis and thrombocytopenia: a retrospective chart review","volume":"9","author":"Abbas","year":"2025","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1585201\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T04:13:37Z","timestamp":1752639217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1585201\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":17,"alternative-id":["10.3389\/fonc.2025.1585201"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1585201","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"article-number":"1585201"}}